NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Restricted access

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

  • 1.

    Landrum LM, Java J, Mathews CA, . Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013;130:12–18.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am 2012;26:93–109.

  • 3.

    Fleming GF, Seidman J, Lengyel E, . Epithelial ovarian cancer. In: Chi DS, Berchuck A, Dizon DS, eds. Principles and Practice of Gynecologic Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017:611–705.

    • Search Google Scholar
    • Export Citation
  • 4.

    Whitney CW, Spirtos N. Gynecologic Oncology Group surgical procedures manual. Philadelphia, PA: Gynecologic Oncology Group; 2010.

  • 5.

    Vergote I, Tropé CG, Amant F, . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–953.

  • 6.

    Kehoe S, Hook J, Nankivell M, . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249–257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Fagotti A, Ferrandina G, Vizzielli G, . Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer 2016;59:22–33.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Onda T, Satoh T, Saito T, . Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016;64:22–31.

    • Search Google Scholar
    • Export Citation
  • 9.

    Liu EL, Mi RR, Wang DH, . Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites. Eur J Gynaecol Oncol 2017;38:209–213.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    van Meurs HS, Tajik P, Hof MH, . Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer 2013;49:3191–3201.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Tajik P, van de Vrie R, Zafarmand MH, . The FIGO stage IVA versus IVB of ovarian cancer: prognostic value and predictive value for neoadjuvant chemotherapy. Int J Gynecol Cancer 2018;28:453–458.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433–443.

  • 13.

    Vergote I, Coens C, Nankivell M, . Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 2018;19:1680–1687.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Armstrong DK, Bundy B, Wenzel L, . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.

  • 15.

    Chi DS, Musa F, Dao F, . An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012;124:10–14.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Wright AA, Bohlke K, Armstrong DK, . Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 2016;143:3–15.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Yedema CA, Kenemans P, Wobbes T, . Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13:18–26.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Buamah PK, Rake MO, Drake SR, . Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer. J Surg Oncol 1990;44:97–99.

  • 19.

    Sørensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58:A4331.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Tewari KS, Java JJ, Eskander RN, . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol 2016;27:114–121.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Timmermans M, van der Aa MA, Lalisang RI, . Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol 2018;150:446–450.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Tiersten AD, Liu PY, Smith HO, . Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 2009;112:444–449.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Pölcher M, Mahner S, Ortmann O, . Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer—a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 2009;22:605–613.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Daniele G, Lorusso D, Scambia G, . Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol 2017;144:256–259.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Garcia YG, Juan AD, Mendiola C, . Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)‏ (GEICO 1205/NOVA TRIAL) [abstract]. J Clin Oncol 2017;35(Suppl):–Abstract 5508.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Rouzier R, Gouy S, Selle F, . Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 2017;70:133–142.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Provencher DM, Gallagher CJ, Parulekar WR, . OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol 2018;29:431–438.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Walker JL, Brady MF, Wenzel L, . Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2019;37:1380–1390.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Markman M, Bundy BN, Alberts DS, . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–1007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Alberts DS, Liu PY, Hannigan EV, . Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    van de Vaart PJ, van der Vange N, Zoetmulder FA, . Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148–154.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Panteix G, Beaujard A, Garbit F, . Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002;22(2B):1329–1336.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Ohno S, Siddik ZH, Kido Y, . Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol 1994;34:302–306.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Spiliotis J, Vaxevanidou A, Sergouniotis F, . The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 2011;16:74–79.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Spiliotis J, Halkia E, Lianos E, . Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22:1570–1575.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Lim MC, Chang SJ, Yoo HJ, . Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 5520.

    • Crossref
    • Export Citation
  • 37.

    van Driel WJ, Koole SN, Sikorska K, . Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230–240.

  • 38.

    Cotte E, Glehen O, Mohamed F, . Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 2007;31:1813–1820.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Di Giorgio A, Naticchioni E, Biacchi D, . Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113:315–325.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Fagotti A, Costantini B, Vizzielli G, . HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 2011;122:221–225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Lim MC, Kang S, Choi J, . Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 2009;16:993–1000.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Deraco M, Kusamura S, Virzì S, . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 2011;122:215–220.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Ansaloni L, Agnoletti V, Amadori A, . Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2012;22:778–785.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Ceelen WP, Van Nieuwenhove Y, Van Belle S, . Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 2012;19:2352–2359.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Tentes AA, Kakolyris S, Kyziridis D, . Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol 2012;2012:358341.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 2013;39:1109–1115.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Coccolini F, Campanati L, Catena F, . Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 2015;26:54–61.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Gouy S, Ferron G, Glehen O, . Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol 2016;142:237–242.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Manzanedo I, Pereira F, Pérez-Viejo E, . Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol 2017;69:119–127.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Paris I, Cianci S, Vizzielli G, . Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Hyperthermia 2018;35:370–374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Lee YJ, Lee JY, Cho MS, . Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. J Gynecol Oncol 2019;30:e3.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Fagotti A, Paris I, Grimolizzi F, . Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 2009;113:335–340.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Massari R, Barone M, Basilico R, . Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study. Minerva Chir 2014;69:17–26.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Montori G, Coccolini F, Fugazzola P, . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience. J Gastrointest Oncol 2018;9:241–253.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Ba M, Long H, Zhang X, . Hyperthermic intraperitoneal perfusion chemotherapy and cytoreductive surgery for controlling malignant ascites from ovarian cancer. Int J Gynecol Cancer 2016;26:1571–1579.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56.

    Suh DH, Lee KH, Kim K, . Major clinical research advances in gynecologic cancer in 2014. J Gynecol Oncol 2015;26:156–167.

  • 57.

    Gelmon KA, Tischkowitz M, Mackay H, . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852–861.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Audeh MW, Carmichael J, Penson RT, . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245–251.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Fong PC, Yap TA, Boss DS, . Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512–2519.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Ledermann J, Harter P, Gourley C, . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382–1392.

  • 61.

    Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets Ther 2013;6:107–118.

  • 62.

    Pujade-Lauraine E, Ledermann JA, Selle F, . Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1274–1284.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Friedlander M, Matulonis U, Gourley C, . Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119:1075–1085.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Olaparib tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, Inc.; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf.

    • Export Citation
  • 65.

    Bevacizumab injection [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2019. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085.

    • Export Citation
  • 66.

    Rucaparib tablets [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf.

    • Export Citation
  • 67.

    Niraparib capsules [prescribing information]. Waltham, MA: TESARO Inc.; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf.

    • PubMed
    • Export Citation
  • 68.

    Moore K, Colombo N, Scambia G, . Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495–2505.

  • 69.

    Friedlander M, Rau J, Lee CK, . Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol 2018;29:737–743.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Burger RA, Brady MF, Bookman MA, . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473–2483.

  • 71.

    Oza AM, Cook AD, Pfisterer J, . Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;16:928–936.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Ferriss JS, Java JJ, Bookman MA, . Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol 2015;139:17–22.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Norquist BM, Brady MF, Harrell MI, . Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group study. Clin Cancer Res 2018;24:777–783.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Markman M, Liu PY, Wilczynski S, . Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–2465.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Markman M, Liu PY, Moon J, . Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009;114:195–198.

    • Search Google Scholar
    • Export Citation
  • 76.

    Pecorelli S, Favalli G, Gadducci A, . Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27:4642–4648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Copeland LJ, Brady MF, Burger RA, . A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: an NRG Oncology study [abstract]. Gynecol Oncol 2017;145:219.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    du Bois A, Floquet A, Kim JW, . Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32:3374–3382.

  • 79.

    Pazopanib tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022465s024s025lbl.pdf.

    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5245 5245 957
PDF Downloads 1972 1972 395
EPUB Downloads 0 0 0